Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Notes Payables (2016 - 2019)

Ironwood Pharmaceuticals (IRWD) has disclosed Notes Payables for 5 consecutive years, with $48.8 million as the latest value for Q2 2019.

  • Quarterly Notes Payables rose 96.28% to $48.8 million in Q2 2019 from the year-ago period, while the trailing twelve-month figure was $48.8 million through Jun 2019, up 96.28% year-over-year, with the annual reading at $47.6 million for FY2018, N/A changed from the prior year.
  • Notes Payables hit $48.8 million in Q2 2019 for Ironwood Pharmaceuticals, up from $46.0 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $48.8 million in Q2 2019 to a low of $8.4 million in Q3 2016.
  • Historically, Notes Payables has averaged $28.2 million across 4 years, with a median of $25.0 million in 2015.
  • Biggest five-year swings in Notes Payables: crashed 58.23% in 2016 and later skyrocketed 284.35% in 2019.
  • Year by year, Notes Payables stood at $25.0 million in 2015, then tumbled by 66.33% to $8.4 million in 2016, then surged by 465.78% to $47.6 million in 2018, then rose by 2.61% to $48.8 million in 2019.
  • Business Quant data shows Notes Payables for IRWD at $48.8 million in Q2 2019, $46.0 million in Q1 2019, and $47.6 million in Q4 2018.